Wet age-related macular degeneration is the leading cause of blindness in the older U.S. population. It is estimated that there are about 1.6 million people with wet AMD in the U.S. There are several approved treatments for wet AMD, mostly in the form of anti-VEGF eye injections. These include Roche's Lucentis and Vabysmo; Regeneron's Eylea and Eylea HD; and Novartis' Beovu. There are also approved biosimilar drugs, such as Byooviz from Samsung Bioepis and Biogen, and Cimerli from Coherus BioSciences, for wet AMD.
The stock we are bringing to your attention today is that of Ocular Therapeutix Inc. (OCUL), which is also developing a treatment for wet AMD.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com